Proton Intelligence secures seed funding to pioneer continuous potassium monitoring for kidney disease patients

Vancouver, Canada, and Melbourne, Australia— Proton Intelligence Inc., a trailblazer in continuous biomarker monitoring, has announced a significant milestone: the successful closure of a $6.95 million seed funding round. Backed by leading investors, including SOSV, We Venture Capital, Tenmile, LongeVC, 15th Rock, Exor, and Trampoline Venture Partners, this financing will enable the company to advance its groundbreaking Continuous Potassium Monitoring (CKM) platform into human trials.

Revolutionising Care for Cardio-Kidney-Metabolic Diseases

Proton Intelligence is transforming the management of cardio-kidney-metabolic diseases through its CKM platform, which delivers on-demand potassium level monitoring. Potassium is a critical biomarker in these diseases, yet it remains notoriously difficult to measure effectively. Erratic potassium levels, whether excessively high or low, can result in severe health consequences, including cardiac arrhythmias and sudden cardiac death.

Unlike traditional diagnostic methods, the CKM platform offers a continuous, remote monitoring solution akin to glucose monitoring for diabetes. This innovation addresses a significant gap in the care of chronic kidney disease (CKD) and heart failure (HF) patients, where managing potassium fluctuations is a pivotal yet challenging aspect of therapy.

The inability to monitor potassium levels in real time often forces clinicians to discontinue life-saving treatments prematurely. Approximately one-third of CKD and HF patients halt essential therapies after experiencing high potassium events, leading to a stark 40% increase in six-month mortality rates.

Strategic Funding to Drive Innovation

Dr. Sahan Ranamukhaarachchi, Founder and CEO of Proton Intelligence, emphasized the transformative potential of the CKM platform, noting that the funding would propel the company through multiple clinical feasibility trials and toward a pivotal study in 2026. This progress brings Proton closer to realising its vision of revolutionising care for millions of patients with chronic kidney disease and related conditions.

Investors have lauded the company’s technological advancements and its potential to fill a critical gap in healthcare. Mohan S. Iyer, General Partner at SOSV, expressed confidence in Proton’s mission, commending its focus and execution. Similarly, Dr. Louise Warme, Head of We Venture Capital, highlighted the breakthrough nature of the CKM platform in addressing dyskalemia—a condition marked by dangerous potassium imbalances.

Clinical Trials to Address an Urgent Need

Proton Intelligence is already conducting clinical studies to evaluate the efficacy of CKM in patients with end-stage renal disease (ESRD) and late-stage CKD. These conditions disproportionately affect millions of individuals globally, placing immense strain on healthcare systems. In the United States alone, CKD affects 14% of adults, accounting for more than a quarter of Medicare spending. Meanwhile, ESRD patients contribute to approximately 7% of Medicare expenditures annually.

The CKM platform’s ability to provide continuous potassium data offers an unprecedented opportunity for clinicians to tailor treatments, improving patient outcomes while potentially reducing healthcare costs. Dr. Steve Burnell, Managing Director at Tenmile, underscored the dual impact of the technology: enhancing patient care and alleviating financial burdens on health systems.

A Leap Toward the Future of Healthcare

The $6.95 million seed funding represents more than financial backing; it is a vote of confidence in Proton Intelligence’s ability to redefine the management of chronic diseases. With plans for pivotal trials and broader implementation on the horizon, the company is poised to revolutionise healthcare through data-driven, patient-centric solutions.

“Our mission is clear—to bring continuous potassium monitoring to millions of patients worldwide,” said Dr. Ranamukhaarachchi. “This milestone is a testament to our team’s dedication and the unwavering support of our investors, who share our vision of transforming cardio-kidney-metabolic care.”